(3R,4S)-4-氨基-3-甲氧基哌啶-1-羧酸叔丁酯 | 1171124-68-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (3R,4S)-4-氨基-3-甲氧基哌啶-1-羧酸叔丁酯
• 英文名称: (3R,4S)-4-amino-1-Boc-3-methoxypiperidinev
• 英文别名: (3R,4S)-4-Amino-1-boc-3-methoxypiperidine；tert-butyl (3R,4S)-4-amino-3-methoxypiperidine-1-carboxylate
• CAS: 1171124-68-7；1363378-22-6
• 化学式: C₁₁H₂₂N₂O₃
• 分子量: 230.307
• InChiKey: QNGHCFVWYKWWMU-DTWKUNHWSA-N

物化性质

• 沸点：
  306.2±42.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,5-二溴吡啶 、 (3R,4S)-4-氨基-3-甲氧基哌啶-1-羧酸叔丁酯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以5.3 g的产率得到(3R,4S)-4-(5-bromopyridin-3-ylamino)-3-methoxypiperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2

  摘要：

  本发明涉及以下式（I）的化合物： 或其药用可接受的盐，其中R 1 ，R 2 ，X，Y和HET如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和紊乱的方法，制备这些化合物的方法以及在这些过程中有用的中间体。

  公开号：

  US20180072703A1

文献信息

• HALO-SUBSTITUTED PYRIMIDODIAZEPINES
  申请人：Cai Jianping

  公开号：US20090318408A1

  公开（公告）日：2009-12-24

  The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.

  本发明提供了PLK1抑制剂化合物I式：用于治疗或控制细胞增殖性疾病，特别是肿瘤性疾病。这些化合物和含有这些化合物的制剂可能对实体瘤的治疗或控制有用，例如乳腺、结肠、肺和前列腺肿瘤以及非何杰金淋巴瘤等其他肿瘤性疾病。还提供了在化合物I式的合成中有用的中间体化合物。
• Halo-substituted pyrimidodiazepines
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08003785B2

  公开（公告）日：2011-08-23

  The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.

  本发明提供了公式I的PLK1抑制剂化合物：用于治疗或控制细胞增殖性疾病，特别是肿瘤性疾病。这些化合物和含有这些化合物的配方可能对实体瘤的治疗或控制有用，例如乳腺癌、结肠癌、肺癌和前列腺癌等肿瘤，以及非霍奇金淋巴瘤等其他肿瘤性疾病。还提供了用于合成公式I化合物的中间体化合物。
• IMIDAZOLE CARBONYL COMPOUND
  申请人：Daiichi Sankyo Company, Limited

  公开号：US20140073622A1

  公开（公告）日：2014-03-13

  To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.

  为了开发一种具有新型作用机制的抗生素，本发明者寻找具有以下特点的化合物：细胞毒性较弱、在水中溶解度高、能够抑制DNA旋转酶GyrB和拓扑异构酶IV ParE亚基，以及具有足够的抗菌活性。结果，本发明者通过发现本发明的一般式（1）所表示的化合物、其药理学可接受的盐和前药具有理想的特性来完成了本发明。本发明提供了一种药物组合物（特别是用于预防或治疗传染病的组合物），其包括由公式（1）所表示的化合物、其药理学可接受的盐或前药作为活性成分。
• Imidazole carbonyl compound
  申请人：Soneda Tsuyoshi

  公开号：US08536197B2

  公开（公告）日：2013-09-17

  An antibiotic compound having a novel mechanism of action, weak cytotoxicity, high solubility in water, effective in inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and having antibacterial activity.

  一种抗生素化合物，具有新颖的作用机制，细胞毒性较弱，水溶性高，能有效抑制DNA旋转酶GyrB和拓扑异构酶IV ParE亚基，并具有抗菌活性。
• Inhibitors of the Renal Outer Medullary Potassium Channel
  申请人：WALSH Shawn P.

  公开号：US20150299198A1

  公开（公告）日：2015-10-22

  The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

  本发明提供了I式化合物及其药学上可接受的盐，它们是ROMK（Kir1.1）通道的抑制剂。该化合物可用作利尿剂和/或钠利尿剂，以及用于治疗和预防包括高血压、心力衰竭和与过多盐和水潴留有关的医疗状况的药物。